Mezzion Pharma Co Ltd
KOSDAQ:140410
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Nexans SA
F:NXS0
|
FR |
|
High Arctic Energy Services Inc
TSX:HWO
|
CA |
Mezzion Pharma Co Ltd
Research & Development
Mezzion Pharma Co Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Mezzion Pharma Co Ltd
KOSDAQ:140410
|
Research & Development
-₩645.8m
|
CAGR 3-Years
35%
|
CAGR 5-Years
35%
|
CAGR 10-Years
10%
|
|
|
Yuhan Corp
KRX:000100
|
Research & Development
-₩198.2B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-18%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Research & Development
-₩169.7B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Research & Development
-₩195.8B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-2%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Research & Development
-₩8.7B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
17%
|
CAGR 10-Years
-9%
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Research & Development
-₩5.7B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
Mezzion Pharma Co Ltd
Glance View
Mezzion Pharma Co., Ltd. engages in the development, production, and licensing of pharmaceutical products. The company is headquartered in Seoul, Seoul. The company went IPO on 2012-01-20. The firm focuses on development and manufacture of remedies for erectile dysfunction and benign prostatic hyperplasia. In addition, the Company engages in the development of remedies for portal hypertension (PH), pulmonary arterial hypertension (PAH), overactive bladder (OAB), chronic obstructive pulmonary disease (COPD) and others. The firm has sighed licensing contract with overseas partners, including Warner in America, Valenta in Russia, Nycomed in Mexico and Dr.Falk in Europe. On April 22, 2013, the Company changed its name from Dong-A Pharmtech Co., Ltd. to Mezzion Pharma Co., Ltd.
See Also
What is Mezzion Pharma Co Ltd's Research & Development?
Research & Development
-645.8m
KRW
Based on the financial report for Sep 30, 2025, Mezzion Pharma Co Ltd's Research & Development amounts to -645.8m KRW.
What is Mezzion Pharma Co Ltd's Research & Development growth rate?
Research & Development CAGR 10Y
10%
The average annual Research & Development growth rates for Mezzion Pharma Co Ltd have been 35% over the past three years , 35% over the past five years , and 10% over the past ten years .
